Skip to content

Mirum Pharmaceuticals, Inc. MIRM Free cash flow margin

Free cash flow margin at other companies

Gilead Sciences logo
Gilead SciencesGILD
34.4%+0.1pp
Rhythm Pharmaceuticals, Inc. logo
Rhythm Pharmaceuticals, Inc.RYTM
-61.5%-14.1pp
Arrowhead Research logo
Arrowhead ResearchARWR
1.8%+0.9pp
LQD
Liquidia CorporationLQDA
-150.7%-64.4pp
Alkermes logo
AlkermesALKS
14.2%-17.6pp
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-77.4%+35.3pp

Other financials

Income statement

See full
Revenue$159.9M+43.3%
Operating income-$789.5M-5,100%
Net income-$790.2M-5,284%
EPS (diluted)-$13.43-4,377%

Balance sheet

See full
Cash & equivalents$261.5M+43.5%
Total debt$13.5M+56.4%
Total equity$242.5M+4.0%
Total assets$890.9M+29.1%

Cash flow

See full
Operating cash flow-$228.8M-11,566%
CapEx$664.0K+1,520%
Free cash flow-$229.4M-11,360%

Valuation

See full
Market cap$6.53B+152%
Enterprise value$6.28B+162%
P/S11.5×+4.6×

Profitability

See full
Operating margin-139.8%-168pp
Net margin-140.2%-169pp

Returns & leverage

See full
Return on equity-335.8%-377pp
Debt / equity0.1×0.0×
Current ratio2.1×-1.1×

Where this comes from

Calculated from Mirum Pharmaceuticals, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Mirum Pharmaceuticals, Inc.'s free cash flow margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Mirum Pharmaceuticals, Inc.'s free cash flow margin?
Mirum Pharmaceuticals, Inc. (MIRM) reported free cash flow margin of -30.3% in Q1 2026.
What is the long-term trend for Mirum Pharmaceuticals, Inc.'s free cash flow margin?
Over 3 years (2021 to 2025), Mirum Pharmaceuticals, Inc.'s free cash flow margin has grown at a -75.2% compound annual growth rate (CAGR), from -693.8% to 10.5%.
What does free cash flow margin mean?
Free cash flow (operating cash flow minus capital expenditures) as a percentage of revenue, trailing twelve months. Measures how efficiently revenue converts into discretionary cash.